THERAVANCE BIOPHARMA INC (TBPH) Fundamental Analysis & Valuation

NASDAQ:TBPH • KYG8807B1068

Current stock price

16.46 USD
+0.15 (+0.92%)
At close:
16.46 USD
0 (0%)
After Hours:

This TBPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TBPH Profitability Analysis

1.1 Basic Checks

  • In the past year TBPH has reported negative net income.
  • In the past year TBPH had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TBPH reported negative net income in multiple years.
  • TBPH had negative operating cash flow in 4 of the past 5 years.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

1.2 Ratios

  • TBPH has a Return On Assets of 21.81%. This is amongst the best in the industry. TBPH outperforms 97.38% of its industry peers.
  • TBPH has a Return On Equity of 35.69%. This is amongst the best in the industry. TBPH outperforms 95.81% of its industry peers.
Industry RankSector Rank
ROA 21.81%
ROE 35.69%
ROIC N/A
ROA(3y)-2.86%
ROA(5y)16.36%
ROE(3y)-7.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • With an excellent Profit Margin value of 98.54%, TBPH belongs to the best of the industry, outperforming 98.95% of the companies in the same industry.
  • TBPH's Profit Margin has declined in the last couple of years.
  • The Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 98.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-61.3%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TBPH Health Analysis

2.1 Basic Checks

  • TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TBPH has more shares outstanding
  • Compared to 5 years ago, TBPH has less shares outstanding
  • TBPH has a better debt/assets ratio than last year.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • TBPH has an Altman-Z score of 1.35. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.35, TBPH perfoms like the industry average, outperforming 52.88% of the companies in the same industry.
  • The Debt to FCF ratio of TBPH is 0.14, which is an excellent value as it means it would take TBPH, only 0.14 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of TBPH (0.14) is better than 96.86% of its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that TBPH is not too dependend on debt financing.
  • The Debt to Equity ratio of TBPH (0.11) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 0.14
Altman-Z 1.35
ROIC/WACCN/A
WACC9.54%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • TBPH has a Current Ratio of 10.93. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
  • TBPH's Current ratio of 10.93 is amongst the best of the industry. TBPH outperforms 80.10% of its industry peers.
  • A Quick Ratio of 10.93 indicates that TBPH has no problem at all paying its short term obligations.
  • TBPH's Quick ratio of 10.93 is amongst the best of the industry. TBPH outperforms 80.63% of its industry peers.
Industry RankSector Rank
Current Ratio 10.93
Quick Ratio 10.93
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TBPH Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.38% over the past year.
  • TBPH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.21% yearly.
  • Looking at the last year, TBPH shows a very strong growth in Revenue. The Revenue has grown by 66.92%.
  • The Revenue has been growing by 8.37% on average over the past years. This is quite good.
EPS 1Y (TTM)51.38%
EPS 3Y-44.21%
EPS 5YN/A
EPS Q2Q%167.74%
Revenue 1Y (TTM)66.92%
Revenue growth 3Y27.95%
Revenue growth 5Y8.37%
Sales Q2Q%144.7%

3.2 Future

  • TBPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.02% yearly.
  • TBPH is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.61% yearly.
EPS Next Y461.81%
EPS Next 2Y67.92%
EPS Next 3Y40.27%
EPS Next 5Y37.02%
Revenue Next Year2.61%
Revenue Next 2Y-12.64%
Revenue Next 3Y-7.24%
Revenue Next 5Y-1.61%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

6

4. TBPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 8.58, the valuation of TBPH can be described as very reasonable.
  • TBPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. TBPH is cheaper than 91.62% of the companies in the same industry.
  • TBPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.29.
Industry RankSector Rank
PE N/A
Fwd PE 8.58
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TBPH indicates a rather cheap valuation: TBPH is cheaper than 97.38% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.55
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • TBPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TBPH's earnings are expected to grow with 40.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.92%
EPS Next 3Y40.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBPH Dividend Analysis

5.1 Amount

  • TBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TBPH Fundamentals: All Metrics, Ratios and Statistics

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (4/24/2026, 8:10:20 PM)

After market: 16.46 0 (0%)

16.46

+0.15 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-06
Inst Owners98.08%
Inst Owner Change0.02%
Ins Owners3.97%
Ins Owner Change-3.94%
Market Cap847.53M
Revenue(TTM)107.46M
Net Income(TTM)105.89M
Analysts76.92
Price Target17.54 (6.56%)
Short Float %10.64%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)35.18%
Min EPS beat(2)-83.12%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-31.1%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-25.63%
EPS beat(12)3
Avg EPS beat(12)-22.22%
EPS beat(16)4
Avg EPS beat(16)-34.32%
Revenue beat(2)0
Avg Revenue beat(2)-12.45%
Min Revenue beat(2)-23.1%
Max Revenue beat(2)-1.81%
Revenue beat(4)0
Avg Revenue beat(4)-7.23%
Min Revenue beat(4)-23.1%
Max Revenue beat(4)-1.36%
Revenue beat(8)3
Avg Revenue beat(8)-2.66%
Revenue beat(12)4
Avg Revenue beat(12)-4.96%
Revenue beat(16)5
Avg Revenue beat(16)-5.48%
PT rev (1m)-35.61%
PT rev (3m)-35.61%
EPS NQ rev (1m)169.11%
EPS NQ rev (3m)172.03%
EPS NY rev (1m)98.94%
EPS NY rev (3m)98.94%
Revenue NQ rev (1m)-23.36%
Revenue NQ rev (3m)-27.15%
Revenue NY rev (1m)-0.95%
Revenue NY rev (3m)13.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.58
P/S 7.89
P/FCF 3.55
P/OCF 3.55
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)1.92
Fwd EY11.65%
FCF(TTM)4.63
FCFY28.14%
OCF(TTM)4.63
OCFY28.15%
SpS2.09
BVpS5.76
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 21.81%
ROE 35.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 98.54%
GM N/A
FCFM 221.93%
ROA(3y)-2.86%
ROA(5y)16.36%
ROE(3y)-7.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-61.3%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 0.14
Debt/EBITDA N/A
Cap/Depr 2.58%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 225.22%
Current Ratio 10.93
Quick Ratio 10.93
Altman-Z 1.35
F-Score9
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)48.78%
Cap/Depr(5y)43.87%
Cap/Sales(3y)1.63%
Cap/Sales(5y)2.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.38%
EPS 3Y-44.21%
EPS 5YN/A
EPS Q2Q%167.74%
EPS Next Y461.81%
EPS Next 2Y67.92%
EPS Next 3Y40.27%
EPS Next 5Y37.02%
Revenue 1Y (TTM)66.92%
Revenue growth 3Y27.95%
Revenue growth 5Y8.37%
Sales Q2Q%144.7%
Revenue Next Year2.61%
Revenue Next 2Y-12.64%
Revenue Next 3Y-7.24%
Revenue Next 5Y-1.61%
EBIT growth 1Y91.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2109.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2167.98%
OCF growth 3YN/A
OCF growth 5YN/A

THERAVANCE BIOPHARMA INC / TBPH Fundamental Analysis FAQ

What is the fundamental rating for TBPH stock?

ChartMill assigns a fundamental rating of 5 / 10 to TBPH.


What is the valuation status for TBPH stock?

ChartMill assigns a valuation rating of 6 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Fairly Valued.


Can you provide the profitability details for THERAVANCE BIOPHARMA INC?

THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.


What is the earnings growth outlook for THERAVANCE BIOPHARMA INC?

The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 461.81% in the next year.